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Most of the individuals infected with SARS coronavirus (SARS-CoV) spontaneously recovered without clinical intervention.
However, the immunological correlates associated with patients’ recovery are currently unknown. In this report, we have
sequentially monitored 30 recovered patients over a two-year period to characterize temporal changes in SARS-CoV-specific
antibody responses as well as cytotoxic T cell (CTL) responses. We have found persistence of robust antibody and CTL
responses in all of the study subjects throughout the study period, with a moderate decline one year after the onset of
symptoms. We have also identified two potential major CTL epitopes in N proteins based on ELISPOT analysis of pooled
peptides. However, despite the potent immune responses and clinical recovery, peripheral lymphocyte counts in the recovered
patients have not yet been restored to normal levels. In summary, our study has, for the first time, characterized the temporal
and dynamic changes of humoral and CTL responses in the natural history of SARS-recovered individuals, and strongly
supports the notion that high and sustainable levels of immune responses correlate strongly with the disease outcome. Our
findings have direct implications for future design and development of effective therapeutic agents and vaccines against
SARS-CoV infection.
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INTRODUCTION
SARS, or severe acute respiratory syndrome, is a serious re-
spiratory illness caused by a novel variant of coronavirus (SARS-
associated coronavirus, SARS-CoV) [1–8]. Others and we have
previously demonstrated that the persistent and high levels of N
protein-specific and S glycoprotein-specific neutralizing antibody
(Nab) responses during the first several weeks of infection are
correlated with the disease outcomes [9–15]. However, little is
known about magnitude and longevity of the both humoral and
CTL responses after prolonged recovery. Studying the long-term
changes in humoral and CTL responses in recovered patients will
not only verify the earlier findings from short-term follow-ups but
also to further establish correlates of protection to be generated by
future vaccine candidates.
RESULTS
Starting in March 2003, we have enrolled and sequentially
followed up 30 patients who were diagnosed and recovered from
SARS-CoV infection according to clinical criteria released by the
World Health Organization (http://www.who.int/csr/sars/case-
definition/en). Sequential blood samples were collected at 1, 3, 6,
12 and 24 months after the onset of symptoms from the enrolled
patients at the Department of Infectious Diseases, Peking Union
Medical College Hospital in Beijing under the guidelines of the
ethical review committee at Hospital. Recovered patients were
defined as those free from the acute illness (high body temperature,
dry cough or light-white sputum, shortness of breath, hypoxia, and
air-space consolidation in lungs) approximately 1 month after the
onset of symptom with definitive sero-positivity against SARS-
CoV lysates at least two consecutive occasions. Clinically, these
recovered patients regain their normal body temperature,
experience no cough or chest pain, and have normal chest
radiograph and normal pulmonary function. The average age of
these patients were 37611 with 13 are being male and 17 female.
All the participating patients were antibody and antigen negative
for HIV-1, cytomegalovirus (CMV), and Epstein-Barr virus (EBV).
For purposes of comparison, blood samples were also obtained
from 70 normal healthy age matched individuals. The average age
for these individuals is 39610 with 36 are being male and 34
female.
Using flow cytometry, we first studied the sequential changes in
the absolute numbers of total lymphocytes, CD3, CD4, CD8 T
lymphocytes, B lymphocytes and natural killer (NK) cells over the
two years follow-ups and compared with that from normal healthy
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PLoS ONE | www.plosone.org 1 December 2006 | Issue 1 | e24controls. As show in Fig. 1, recovered patients clearly experienced
two distinct phases of cell restoration in the peripheral blood; an
initial rapid phase for all the cell populations studied in the first
3 months after the onset of symptoms followed by a significant
slower phase during the subsequent months. During the first
3 months, the average increase for the cell populations studied was
as high as 22% per month. The mean absolute total lymphocytes,
CD3, CD4, and CD8 T lymphocytes, B lymphocytes and NK cells
has increased from 1349 to 1870 cells/mm
3, 1130 to 1268 cells/
mm
3, 511 to 591 cells/mm
3, 440 to 547 cells/mm
3, 120 to 152
cells/mm
3, and 103 to 254 cells/mm
3, respectively. The rapid
phase for lymphocyte recovery is reminescinet of what had
reported through the cross-sectional studies on the recovered
SARS patients during the first few weeks of onset of symptom
[2,7,8,16,17]. As we and others shown previously, the initial rapid
phase in peripheral lymphocyte recovery usually coincided with
the improving clinical condition of SARS patients [2,7,8,16,17].
After the first 3 months, however, the percent of increase dropped
to 0.07% per month and, in most cases, remained unchanged or
slightly decreased from the previous time points (Fig. 1). Such
distinct rate of lymphocyte recovery in the two phases is likely
reflective of different mechanisms in lymphocyte regeneration,
proliferation and distribution in vivo. Furthermore, with the
exception for B lymphocytes, the mean absolute numbers for
total lymphocytes, CD3, CD4, CD8 T lymphocytes, and NK cells
at 24 months after the onset of symptom remained statistically
different from that in normal healthy age-matched controls. This
finding suggests that complete restoration of peripheral lympho-
cyte may require a longer period or peripheral lymphocyte
reduction in SARS patients is permanent despite of recovery from
clinical manifestation of SARS-CoV infection. Longer follow-ups
of these patients will be needed to address these two possibilities.
To study the sequential changes in humoral responses against
SARS-CoV, we used our previously published ELISA-based and
pseudotyped retrovirus-based neutralization systems [11]. We first
analyzed the temporal changes in total serum IgG specific for
SARS-CoV, using a commercially available ELISA assay (No
S20030004, HuaDa Comp, Beijing, China) based on purified
whole virus lysates. As shown in Fig. 2A, there was an initial
increase in total IgG from month 1 to 3 after onset of symptom
followed by a gradual decrease over the ensuing period. In fact,
much of the decrease was observed during month 3 to 18 after
onset of symptom with no significant changes were found
afterwards (Fig. 2A). In addition, we also characterized temporal
changes in N protein-specific antibody and S glycoprotein-specific
neutralizing antibody (Nab) responses in these patients. Our
experiments were conducted with serum samples in two different
dilutions (1/100 and 1/900) and Fig. 2B depicts the temporal
changes in N protein-specific antibodies over the 24-month follow-
up based on N protein-based ELISA. We have found that
antibodies against N protein were detectable throughout the entire
period of study. Within the first 6 month after onset of symptom,
N protein-specific antibody remained relatively high although
there is a clear trend of decrease over time, with more significant
drop in titers between month 6 and 12 after onset of symptom and
no dramatic changes afterwards (Fig. 2B). The same trend of
changes in N protein-specific antibodies was also observed for
experiments conducted with 1/900 dilution (Fig. 2B). In regard to
S glycoprotein-specific Nab, we used our previously published
pseudotyped retroviral system with S glycoprotein on the surface
Figure 1. Sequential analysis of peripheral changes in total lymphocytes (LY), CD3, CD4, CD8, B cell, and NK cell counts in recovered patients over 2-
year period after onset of symptom. Grey stars indicate the significant differences between the recovered patients at 24 months after onset of
symptom and normal healthy controls. Their respective p values are presented.
doi:10.1371/journal.pone.0000024.g001
Follow-Up of SARS Patients
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with what have been observed for N-protein specific antibodies,
high and sustainable levels of S glycoprotein-specific Nab were
detected throughout the entire phase of study (Fig. 2C). At 1/100
dilution, all samples had potent neutralizing activities capable of
neutralizing at least 60% of input virion, with median level
activities larger than 95% (Fig. 2C). There is also of trend of
decrease in S glycoprotein-specific Nab titer over time, but no
dramatic drop was found between month 6 and 12 as was found
for the N protein-specific antibodies. Lastly, the same trend of
changes in S glycoprotein-specific Nab was also observed for
experiments conducted with 1/900 dilution (Fig. 2C). It remains to
be seen whether the levels of SARS-CoV-specific antibodies will
remain unchanged or continuously decline after 24 months of
follow-up.
To study the sequential changes in CTL responses against
SARS-CoV, we used ELISPOT-based technique to quantify the
number of INF-c releasing cells in the peripheral blood against
peptide pools covering the entire N protein derived from the
Urbani strain [3]. The peptide pools were made of 57 peptides
which are 15–18 amino acid residues in length overlapping by 10
amino acid residues. The peptide pools were obtained through the
Biodefense and Emerging Infections Resources Repository at
National Institute of Health (NIH) in the United States (http://
www.beiresources.org/listing/index.cfm). We first studied the
sequential changes in total number of INF-c releasing cells,
expressed as Spot Forming Cell (SFC) per million PBMC, in the
peripheral blood over the 18 months after onset of symptom.
Fig. 3A shows the average number of INF-c releasing cells
detected at month 3, 12 and 18 after onset of symptom. As
observed for antibody responses, detectable levels of CTL
responses were found throughout the study period, although there
is a clear trend of decrease over time (Fig. 3A). To further identify
the major epitopes recognized by the CTL, the 57 peptides were
further divided into 15 peptide pools in a cross-broad fashion
(NX1-7 vs. NY1-8) (Fig. 4, upper panel). The intensity and
magnitude of CTL responses against the NX1-7 and NY1-8
peptide pools were presented as either the total number of SFC
per million PBMC or the percent of samples having detectable
levels of INF-c releasing cells (Fig. 3B). Fig. 3B summarizes results
for all the samples tested and four peptide pools, namely NX4,
NX6, NY6, and NY7, were found to be preferentially recognized
by recovered SARS patients (Fig. 3B). Through the cross-broad
analysis, we have found that there are potential two major CTL
epitopes in the N protein. One is located within the region covered
by peptides NC9568 and NC9569, and the other is covered by
peptides NC9584 and NC9585 (Fig. 4, upper panel). Peptides
NC9568 and NC9569 correspond to amino acid sequence
MASGGGETALALLLLDRLNQLESKV between positions 211
and 235 in the N protein, whereas peptides NC9584 and NC9585
match the sequence of TWLTYHGAIKLDDKDPQFKDNVILL
between positions 330 and 354 (Fig. 4, lower panel). Serotyping of
MHC class I and II have found that A2, 3, 11 and 24, B51 and 60,
and DR4, 9, 12, and 15, and DQ5, 6, 7, 8, and 9 are the
predominant among our study population (Table 1). Future work
would be required to further fine mapping the actual CTL
epitopes in these two regions and their association with particular
serotypes of MHC class I.
DISCUSSION
In this report, we have extended our early study by sequentially
monitoring 30 recovered SARS patients over a 2-year period to
characterize temporal changes in humoral and CTL responses
against SARS-CoV. We have shown for the first time that
recovered patients have persistent and robust binding as well as
neutralizing antibody and CTL responses throughout the study
period with a moderate decline one year after the onset of
symptoms. In particular, S glycoprotein-specific Nab responses are
persistently high in the recovered patients even 24 months after
onset of symptom. Such high and sustainable levels of SARS-CoV-
specific immune responses in these patients are clear distinction
from that found in patients who succumbed to the disease [11],
suggesting that antibody responses likely play an important role in
determining the ultimate disease outcome of SARS-CoV infected
patients. In addition, we have also identified two potential major
CTL epitopes in N protein based on ELISPOT analysis of 57
peptides. Future work will be required to identify the actual
epitopes in greater details. However, despite the potent immune
Figure 2. Sequential analysis of antibody responses against the whole viral lysates (A), N protein (B), and pseudotyped virus with S protein (C) of
SARS-CoV in 30 recovered patients over 2-year period. Serum samples were diluted 100- and 900-fold prior to ELISA and neutralization studies. Both
dilutions were used to carried out experiments presented in (B) and (C), where the only 100-fold diluted serum were used for experiments presented
in (A). The top and bottom of each rectangular box denote the 75
th and 25
th percentiles, respectively, with the median shown inside the box.
Horizontal bars extending from each box represent the 90
th and 10
th percentiles. Significant differences between samples are indicated by grey stars
with their respective p values. Otherwise no significance was found.
doi:10.1371/journal.pone.0000024.g002
Follow-Up of SARS Patients
PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e24Figure 3. Sequential analysis of CTL responses against a pool of peptides derived from N protein in 30 recovered patients over 2-year period. (A) The
average number of spot forming cells (SFC) per million of PBMC from recovered patients at month 3, 12, and 18 post onset of symptom. No
significant differences were found among these samples. The top and bottom of each rectangular box denote the 75
th and 25
th percentiles,
respectively, with the median shown inside the box. Horizontal bars extending from each box represent the 90
th and 10
th percentiles. (B) The average
number of SFC per million of PBMC against various pools of N protein peptides (open rectangle) and percent of PBMC samples recognizing various
pools of N protein peptides (closed rectangle). An arbitrary line was draw at 3000 SFC per million PBMC to identify peptide pools that are
preferentially recognized by the recovered patients in this cohort.
doi:10.1371/journal.pone.0000024.g003
Figure 4. The actual composition and cross-broad layout of each peptide pools derived from the N protein (upper panel). The 57 peptides (one is not
listed) were pooled into 15 groups, 7 of which (NX1-7) are listed vertically and 8 are (NY1-8) listed horizontally. The actual amino acid residue
sequences preferentially recognized by the recovered patients are highlighted (lower panel), which correspond to residue sequences between
position number 211 to 235 and 330 to 354.
doi:10.1371/journal.pone.0000024.g004
Follow-Up of SARS Patients
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the recovered patients have not yet been restored to normal levels.
This finding suggest that complete restoration of peripheral
lymphocyte may require longer period of time, or the lymphocyte
destruction during SARS-CoV infection is permanent and can
only be repaired partially. In summary, our study has for the first
time characterized the temporal and dynamic changes of humoral
and CTL responses in the natural history of SARS-recovered
individuals and strongly support the notion that high and
sustainable levels of immune responses correlated strongly with
the disease outcome. We strongly believe that our findings have
direct implications for the design and development of therapeutics
and vaccines against SARS-CoV infection and replication.
MATERIALS AND METHODS
Study subjects
Thirty SARS patients were enrolled in March 2003 and have
continuously followed up since then. They were diagnosed and
recovered from SARS-CoV infection according to clinical criteria
released by the World Health Organization (http://www.who.int/
csr/sars/casedefinition/en). Sequential blood samples were col-
lected with their informed consent and approval from the ethical
review committee at the Department of Infectious Diseases, Peking
Union Medical College Hospital in Beijing. The average age of
these patients were 37611 with 13 are being male and 17 female.
For purposes of comparison, blood samples were also obtained
from 70 normal healthy age matched individuals. The average age
for these individuals is 39610 with 36 are being male and 34
female.
Flow cytometry
For flow cytometric analyses of various lymphocyte populations in
the peripheral blood, we used our previously published protocols
[17].
Antibody responses detected by ELISA and
pseudotyped retrovirus
Analysis of binding antibodies against whole SARS-CoV lysates or
N protein, and S glycoprotein-specific neutralizing antibody (Nab)
were conducted as previously reported [11].
ELISPOT assay
ELISPOT assays were performed using a commercially available
kit (Diaclone, France) according to manufacture’s introduction.
The peptide pools covering the entire N protein of the Urbani
strain were used to stimulate patients’ peripheral blood mono-
nuclear cells. The peptide pools were made of 57 peptides which
are 15–18 amino acid residues in length overlapping by 10 amino
acid residues. These peptides were obtained through the
Biodefense and Emerging Infections Resources Repository at
National Institute of Health (NIH) in the United States (http://
www.beiresources.org/listing/index.cfm).
Statistic analysis
Student’s t test analysis was used to determine the significance of
the results. Values of p#0.05 indicated statistical significance.
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